Cargando…

Chromatin Regulators Mediate Anthracycline Sensitivity in Breast Cancer

Anthracyclines are a highly effective component of curative breast cancer chemotherapy, but are associated with significant morbidity(1,2). Since anthracyclines work in part via inhibition of topoisomerase-II (TOP2) on accessible DNA(3,4), we hypothesized that chromatin regulatory genes (CRGs) that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seoane, Jose A., Kirkland, Jacob G., Caswell-Jin, Jennifer L., Crabtree, Gerald R., Curtis, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220800/ https://www.ncbi.nlm.nih.gov/pubmed/31700186 http://dx.doi.org/10.1038/s41591-019-0638-5

Ejemplares similares

Rapid and reversible epigenome editing by endogenous chromatin regulators
por: Braun, Simon M. G., et al.
Publicado: (2017)

RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy
por: Xia, Peng, et al.
Publicado: (2023)

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors
por: Varghese, Sonu S., et al.
Publicado: (2021)

Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
por: de Pinho, Inês Soares, et al.
Publicado: (2023)

SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity
por: Dai, Xiaofeng, et al.
Publicado: (2023)

Anthracyclines in the treatment of patients with early breast cancer
por: Guarneri, V., et al.
Publicado: (2022)

Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells
por: Pandey, Sony, et al.
Publicado: (2018)

Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)

Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
por: Kadoch, Cigall, et al.
Publicado: (2015)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)

Anthracyclines in the treatment of early breast cancer friend or foe?
por: Vuger, Ana Tecic, et al.
Publicado: (2022)

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer
por: Braunstein, Marsela, et al.
Publicado: (2016)

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
por: Abdel-Fatah, Tarek M. A., et al.
Publicado: (2019)

A unified definition of clinical anthracycline resistance breast cancer
por: Pivot, X, et al.
Publicado: (2000)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
por: Munro, A F, et al.
Publicado: (2012)

Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
por: Yaylali, Yalin Tolga, et al.
Publicado: (2016)

A careful reassessment of anthracycline use in curable breast cancer
por: Hurvitz, Sara Alsterlind, et al.
Publicado: (2021)

Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
por: Balaji, Swetha, et al.
Publicado: (2023)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
por: Mulligan, Jude M., et al.
Publicado: (2014)

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
por: Beaudry, Rhys I., et al.
Publicado: (2019)

PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis
por: Zhang, Meilin, et al.
Publicado: (2022)

Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
por: Wang, Yuehan, et al.
Publicado: (2023)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
por: Ladan, Marjolijn M., et al.
Publicado: (2023)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
por: Bansal, Neha, et al.
Publicado: (2019)

Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy
por: Nettersheim, Felix Sebastian, et al.
Publicado: (2023)

A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
por: de la Fuente, Ana, et al.
Publicado: (2022)

Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy
por: Blaes, Anne H, et al.
Publicado: (2015)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer
por: Munkácsy, G, et al.
Publicado: (2010)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
por: Bulten, Ben F., et al.
Publicado: (2015)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
por: Yersal, Özlem, et al.
Publicado: (2018)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment
por: Cai, Fengfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ke81rdbr77duk3s3psk6u66tlk